B. Metzler seel. Sohn & Co. AG Buys 5,322 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

B. Metzler seel. Sohn & Co. AG raised its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 57.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,557 shares of the company's stock after buying an additional 5,322 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in IDEXX Laboratories were worth $6,018,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of IDXX. FSA Wealth Management LLC bought a new stake in IDEXX Laboratories during the 3rd quarter valued at $25,000. Rialto Wealth Management LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at about $30,000. Retirement Wealth Solutions LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at about $31,000. Kestra Investment Management LLC purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth about $38,000. Finally, Crews Bank & Trust bought a new stake in shares of IDEXX Laboratories in the fourth quarter worth about $41,000. 87.84% of the stock is owned by institutional investors.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the company's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the firm's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by insiders.

Remove Ads

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on IDXX shares. Bank of America increased their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Piper Sandler upped their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Morgan Stanley dropped their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th. StockNews.com upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Friday. Finally, Barclays raised their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $533.75.

IDEXX Laboratories Stock Down 4.1 %

Shares of NASDAQ IDXX traded down $17.03 during trading on Friday, reaching $393.73. The company had a trading volume of 1,635,645 shares, compared to its average volume of 592,302. The business's 50-day moving average is $435.55 and its 200 day moving average is $440.31. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The stock has a market cap of $31.91 billion, a PE ratio of 36.90, a P/E/G ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a 12-month low of $393.50 and a 12-month high of $548.88.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.